GAMMA Investing LLC Increases Stake in Insulet Co. (NASDAQ:PODD)

GAMMA Investing LLC grew its position in Insulet Co. (NASDAQ:PODD) by 44.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,424 shares of the medical instruments supplier’s stock after buying an additional 741 shares during the period. GAMMA Investing LLC’s holdings in Insulet were worth $633,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc raised its holdings in Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after acquiring an additional 157 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Insulet by 4.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier’s stock worth $20,065,000 after purchasing an additional 3,355 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Insulet in the third quarter worth $202,000. Synovus Financial Corp lifted its holdings in shares of Insulet by 36.1% during the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock valued at $682,000 after purchasing an additional 777 shares in the last quarter. Finally, Tidal Investments LLC boosted its position in shares of Insulet by 5.2% during the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier’s stock valued at $2,180,000 after buying an additional 466 shares during the last quarter.

Insulet Trading Up 3.7 %

Shares of PODD opened at $266.30 on Friday. The firm has a market cap of $18.68 billion, a P/E ratio of 45.60, a price-to-earnings-growth ratio of 4.12 and a beta of 1.21. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a 50 day simple moving average of $260.30 and a two-hundred day simple moving average of $227.97.

Wall Street Analyst Weigh In

A number of research firms have commented on PODD. Barclays lifted their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Morgan Stanley upped their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Canaccord Genuity Group raised their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Citigroup upped their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, TD Cowen raised their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.